November 2026 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, November 09) published advice on four medicines.

Lisocabtagene maraleucel (Breyanzi®) was accepted for the treatment of adults with certain types of blood cancers, including diffuse large B-cell lymphoma, high grade B‑cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B.

Cemiplimab (Libtayo®) was accepted, when used alone or in combination with chemotherapy, for the first-line treatment of adults with non-small cell lung cancer.

Daratumumab (Darzalex®) used together with bortezomib, lenalidomide, and dexamethasone was accepted for the treatment of adults with newly diagnosed myeloma, who are not suitable for a stem cell transplant.

Garadacimab (Andembry®) was accepted for the routine prevention of frequent severe attacks of hereditary angioedema (HAE) in patients 12 years and older. HAE is a rare inherited condition, causing swelling that can affect any part of the body including the hands, feet, arms, legs, intestines, face and throat. Attacks are unpredictable and can be life threatening.

SMC Co-Vice Chair Dr Jane Goddard said:

“The committee is pleased to be able to accept these new medicines for use by NHSScotland.

“Lisocabtagene maraleucel provides an effective CAR-T cell therapy treatment option for those B-cell lymphoma patients who have relapsed after or not responded to first-line treatment.

“Cemiplimab provides an immunotherapy treatment option for patients with NSCLC, which we know will be welcomed.

“Daratumumab, used in combination, provides an effective first-line treatment option to delay the progression of cancer for patients with myeloma.

“Garadacimab provides a long-term preventative treatment option for patients with hereditary angioedema.”